Cytokinetics (CYTK) has granted equity incentives to 5 new employees who joined in April and May 2025. The package includes 40,275 stock options at an exercise price of $29.84 per share and 27,144 RSUs. The RSUs will vest over 3 years (40% in year 1, 40% in year 2, 20% in year 3), while stock options vest over 4 years with a 10-year term. These grants were made under Nasdaq Rule 5635(c)(4) as employment inducements. Cytokinetics is a cardiovascular biopharmaceutical company developing treatments for cardiac muscle dysfunction, including aficamten for HCM, omecamtiv mecarbil for HFrEF, CK-586 for HFpEF, and CK-089 for muscular dystrophy.
Cytokinetics (CYTK) ha concesso incentivi azionari a 5 nuovi dipendenti assunti ad aprile e maggio 2025. Il pacchetto include 40.275 opzioni su azioni con un prezzo di esercizio di 29,84 $ per azione e 27.144 RSU. Le RSU matureranno in 3 anni (40% nel primo anno, 40% nel secondo, 20% nel terzo), mentre le opzioni su azioni maturano in 4 anni con una durata di 10 anni. Questi incentivi sono stati concessi ai sensi della Regola Nasdaq 5635(c)(4) come stimolo all'assunzione. Cytokinetics è una società biofarmaceutica cardiovascolare che sviluppa trattamenti per la disfunzione del muscolo cardiaco, tra cui aficamten per HCM, omecamtiv mecarbil per HFrEF, CK-586 per HFpEF e CK-089 per la distrofia muscolare.
Cytokinetics (CYTK) ha otorgado incentivos accionarios a 5 nuevos empleados que se unieron en abril y mayo de 2025. El paquete incluye 40,275 opciones sobre acciones con un precio de ejercicio de $29.84 por acción y 27,144 RSU. Las RSU se consolidarán en 3 años (40% en el año 1, 40% en el año 2, 20% en el año 3), mientras que las opciones sobre acciones se consolidan en 4 años con un plazo de 10 años. Estas concesiones se realizaron bajo la Regla Nasdaq 5635(c)(4) como incentivos de empleo. Cytokinetics es una empresa biofarmacéutica cardiovascular que desarrolla tratamientos para la disfunción del músculo cardíaco, incluyendo aficamten para HCM, omecamtiv mecarbil para HFrEF, CK-586 para HFpEF y CK-089 para la distrofia muscular.
Cytokinetics(CYTK)는 2025년 4월과 5월에 입사한 5명의 신입 직원에게 주식 인센티브를 부여했습니다. 패키지에는 주당 행사 가격이 $29.84인 40,275주 주식매수선택권과 27,144 RSU가 포함되어 있습니다. RSU는 3년에 걸쳐 베스팅되며(1년 차 40%, 2년 차 40%, 3년 차 20%), 주식매수선택권은 4년에 걸쳐 베스팅되고 10년 만기입니다. 이 인센티브는 Nasdaq 규칙 5635(c)(4)에 따른 고용 유인책으로 부여되었습니다. Cytokinetics는 심장 근육 기능 장애 치료제를 개발하는 심혈관 생명공학 회사로, HCM 치료제인 아피캄텐(aficamten), HFrEF 치료제인 오메캄티브 메카르빌(omecamtiv mecarbil), HFpEF 치료제 CK-586, 근이영양증 치료제 CK-089를 개발 중입니다.
Cytokinetics (CYTK) a accordé des incitations en actions à 5 nouveaux employés recrutés en avril et mai 2025. Le package comprend 40 275 options d'achat d'actions à un prix d'exercice de 29,84 $ par action et 27 144 RSU. Les RSU seront acquises sur 3 ans (40 % la première année, 40 % la deuxième, 20 % la troisième), tandis que les options d'achat d'actions seront acquises sur 4 ans avec une durée de 10 ans. Ces attributions ont été faites conformément à la règle Nasdaq 5635(c)(4) en tant qu'incitations à l'embauche. Cytokinetics est une société biopharmaceutique cardiovasculaire développant des traitements pour la dysfonction du muscle cardiaque, notamment l'aficamten pour la CMH, l'omecamtiv mecarbil pour l'HFrEF, le CK-586 pour la HFpEF et le CK-089 pour la dystrophie musculaire.
Cytokinetics (CYTK) hat 5 neuen Mitarbeitern, die im April und Mai 2025 eingestellt wurden, Aktienanreize gewährt. Das Paket umfasst 40.275 Aktienoptionen zu einem Ausübungspreis von 29,84 $ pro Aktie sowie 27.144 RSUs. Die RSUs werden über 3 Jahre vesten (40 % im ersten Jahr, 40 % im zweiten Jahr, 20 % im dritten Jahr), während die Aktienoptionen über 4 Jahre mit einer Laufzeit von 10 Jahren vesten. Diese Zuteilungen erfolgten gemäß Nasdaq-Regel 5635(c)(4) als Anreiz bei der Einstellung. Cytokinetics ist ein biopharmazeutisches Unternehmen im Bereich Herz-Kreislauf-Erkrankungen, das Therapien für Herzmuskelstörungen entwickelt, darunter Aficamten für HCM, Omecamtiv Mecarbil für HFrEF, CK-586 für HFpEF und CK-089 für Muskeldystrophie.
Positive
None.
Negative
None.
SOUTH SAN FRANCISCO, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on May 15, 2025 it granted stock options to purchase an aggregate of 40,275 shares of common stock and 27,144 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 5 employees, whose employment commenced in April and May, 2025, as a material inducement to their employment.
The RSUs will vest over 3 years, with 40% of the RSUs vesting on the first anniversary of the applicable grant date, an additional 40% of the RSUs vesting on the second anniversary of the grant date and the final 20% vesting on the third anniversary of the grant date, in each case, subject to each respective employee’s continued service with the Company. The stock options that were granted are subject to an exercise price of $29.84 per share, which is equal to the closing price of the Company’s common stock on May 15, 2025, and will vest over 4 years, with 1/4th of the shares underlying the employee’s option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting in monthly installments at a rate of 1/48th of the shares underlying such stock options over the subsequent 36 months, subject to each respective employee’s continued service with the Company. The stock options have a 10-year term. These awards are subject to the terms and conditions of the Company's Amended and Restated 2004 Equity Incentive Plan and the applicable award agreements pursuant to which the awards were granted.
The stock options and RSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology to advance a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics is readying for potential regulatory approvals and commercialization of aficamten, a cardiac myosin inhibitor following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten, for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities of Cytokinetics’ product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics' business outlined in Cytokinetics' filings with the Securities and Exchange Commission particularly under the caption “Risk Factors” in Cytokinetics’ latest Annual Report on Form 10-K. Forward-looking statements are not guarantees of future performance, and Cytokinetics' actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.
What equity incentives did Cytokinetics (CYTK) grant to new employees in May 2025?
Cytokinetics granted 40,275 stock options at $29.84 per share and 27,144 RSUs to 5 new employees, with RSUs vesting over 3 years and stock options vesting over 4 years.
What is the vesting schedule for Cytokinetics' (CYTK) May 2025 RSU grants?
The RSUs vest over 3 years with 40% vesting in year 1, 40% in year 2, and 20% in year 3, subject to continued employment.
What pipeline products is Cytokinetics (CYTK) currently developing?
Cytokinetics is developing aficamten for HCM, omecamtiv mecarbil for HFrEF, CK-586 for HFpEF, and CK-089 for muscular dystrophy.
What was the exercise price for CYTK's stock options granted in May 2025?
The stock options were granted with an exercise price of $29.84 per share, equal to the closing price on May 15, 2025.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
